BLTE
BELITE BIO, INC
NASDAQ · Healthcare · Biotechnology · US
$146.57
−2.46%Price chart
Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23
Key dataOct 23, 2026
Open$151.20
From 52W high−24.30%
Volume44103.00
Market cap$5.90B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 23, 2026
Open
$151.20
From 52W high
−24.30%
Volume
44103.00
Market cap
$5.90B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−51.7x
P/E (TTM)
—
RSI (14)
39.5
MomentumView details →
1D Return
−2.46%
YTD Return
−7.84%
SummaryUpdated Jun 1, 2026
Belite Bio, Inc (NASDAQ:BLTE) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in San Diego, California. The company operates as a subsidiary of Lin Bioscience International Ltd and went public in April 2022. Belite Bio specializes in developing novel oral therapeutics for rare retinal diseases, particularly focusing on conditions that cause progressive vision loss and blindness. The company's primary focus is on advancing treatments for Stargardt disease and geographic atrophy, two debilitating eye conditions that currently have limited or no approved treatment options.
Similar companies
Latest newsMore news →
BELITE BIO, INC announced that it submitted marketing authorization applications for tinlarebant to regulatory authorities in Singapore, the United Kingdom and Switzerland for Stargardt disease type 1.9d agoBelite Bio announced that data on its tinlarebant for Stargardt disease will be presented at the Innovate Retina conference on October 8, 2026, and at the American Academy of Ophthalmology 2026 meeting on October 9-12, 2026, both in New Orleans, Louisiana.22d agoBelite Bio announced that its data will be presented at the Euretina Innovation Spotlight on September 30, 2026, and at Euretina on October 1-4, 2026, in Vienna, Austria.25d ago